CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Conditions: Fabry Disease

First Posted Date: 2020-09-17

Last Posted Date: 2024-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Registration Number: NCT04552691

Locations: 🇺🇸
University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸
Central Coas Nephrology, Salinas, California, United States

and more 8 locations

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Phase 2

Terminated

Conditions: Acute Respiratory Distress Syndrome

Interventions: Drug: CUROSURF® (poractant alfa)

First Posted Date: 2020-08-06

Last Posted Date: 2023-06-23

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 22

Registration Number: NCT04502433

Locations: 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇮🇹
Chiesi site # 14, Bologna, Italy
🇬🇧
Chiesi site #4, London, United Kingdom

and more 3 locations

ARCANGELO (itAlian pRospective Study on CANGrELOr)

Completed

Conditions: Acute Coronary Syndrome

First Posted Date: 2020-07-15

Last Posted Date: 2022-03-09

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 1005

Registration Number: NCT04471870

Locations: 🇮🇹
Policlinico San Matteo, Pavia, Italy
🇮🇹
A.O.U. Riuniti, Ancona, Italy
🇮🇹
Ospedale San Bassiano, Bassano del Grappa, Italy

and more 27 locations

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

Phase 3

Recruiting

Conditions: COPD
COPD Exacerbation

Interventions: Drug: Beclomethasone Dipropionate
Drug: Glycopyrronium Bromide
Drug: Formoterol Fumarate

First Posted Date: 2020-03-25

Last Posted Date: 2024-10-09

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 2934

Registration Number: NCT04320342

Locations: 🇺🇸
Chiesi Clinical Trial Site 840421, Kingwood, West Virginia, United States
🇺🇸
Chiesi Clinical Trial Site 840201, Morgantown, West Virginia, United States
🇨🇦
Chiesi Clinical Trial Site 124103, Edmonton, Alberta, Canada

and more 440 locations

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

Phase 2

Terminated

Conditions: Neonatal Opioid Withdrawal Syndrome

Interventions: Drug: CHF6563
Drug: Morphine
Drug: Morphine matched placebo
Drug: CHF6563 matched placebo

First Posted Date: 2019-09-26

Last Posted Date: 2023-08-03

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 7

Registration Number: NCT04104646

Locations: 🇺🇸
Clinical site 015, Las Vegas, Nevada, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer

Phase 1

Completed

Conditions: Diabetic Neuropathic Foot Ulcers

Interventions: Biological: CHF6467 active

First Posted Date: 2019-09-04

Last Posted Date: 2022-02-23

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 93

Registration Number: NCT04077671

Locations: 🇧🇬
Comac Medical Ltd., Sofia, Bulgaria

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma

Phase 3

Terminated

Conditions: Asthma; Eosinophilic

Interventions: Drug: Treatment C
Drug: Treatment D
Drug: Treatment B
Drug: Treatment A

First Posted Date: 2019-08-08

Last Posted Date: 2022-04-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 810

Registration Number: NCT04049175

Locations: 🇧🇬
Medical Center "Nov Rehabilitatsionen Tsentar" Ltd, Stara Zagora, Bulgaria

Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects

Phase 1

Completed

Conditions: COPD

Interventions: Drug: CHF6523

First Posted Date: 2019-07-25

Last Posted Date: 2023-01-25

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 136

Registration Number: NCT04032535

Locations: 🇬🇧
Richmond Pharmacology, London, United Kingdom

Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis

Phase 3

Withdrawn

Conditions: Alpha-Mannosidosis

Interventions: Drug: Velmanase Alfa
Drug: Placebo

First Posted Date: 2019-07-24

Last Posted Date: 2020-12-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Registration Number: NCT04031066

A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis

Phase 1

Completed

Conditions: Cystic Fibrosis
Non-Cystic Fibrosis Bronchiectasis

Interventions: Drug: CHF 6333
Drug: Placebo

First Posted Date: 2019-07-08

Last Posted Date: 2021-03-30

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 68

Registration Number: NCT04010799

Locations: 🇩🇪
IKF Institut für klinische Forschung Pneumologie, Frankfurt/Main, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy